EPLive 2022 is a two-day conference that draws the world’s top cardiac electrophysiology experts AUSTIN, Texas, May 20, 2022 /PRNewswire/ — On June 2 and 3, 2022, the Texas Cardiac Arrhythmia Institute (TCAI) at St. David’s Medical Center will host its sixth international symposium on complex arrhythmias, EPLive 2022. EPLive is an intensive, two-day […]
Rhythm
Keros Therapeutics Presents Results from a Preclinical Study of RKER-012 in Pulmonary Arterial Hypertension at the American Thoracic Society International Conference
LEXINGTON, Mass., May 17, 2022 (GLOBE NEWSWIRE) — Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need, today announced results from a preclinical […]
UH uses novel solution during contrast dye shortage
University Hospitals Harrington Heart & Vascular Institute has developed a novel solution for one procedure affected by the nationwide shortage of contrast dye. Cardiologists at the Cleveland hospital recently were the first to report using cardiovascular magnetic resonance imaging (CMR) for left atrial appendage closure preprocedural planning. Left atrial appendage […]
HUYABIO INTERNATIONAL ANNOUNCES COMPLETION OF HBI-3000 PHASE 1 TRIAL AND FDA APPROVAL TO PROCEED WITH DOSE ESCALATION IN PHASE 2
Phase 1 trial evaluated the pharmacokinetics and safety of HBI-3000 when dosed with thestrong CYP2D6 inhibitor, paroxetine SAN DIEGO, May 17, 2022 /PRNewswire/ — HUYABIO International, the leader in accelerating global development of China’s pharmaceutical innovations, today announced the successful completion of a Phase 1 drug-drug interaction clinical trial of HBI-3000, a novel drug for cardioversion […]
egnite, Inc. Expands into Cardiovascular Disease Supported by New Data on the State of Care for Patients with Atrial Fibrillation
Company to focus on improving the quality of care for all cardiovascular patients in the U.S. ALISO VIEJO, Calif.–(BUSINESS WIRE)–On the heels of its landmark valvular heart disease (VHD) prevalence abstract published in Journal of the American College of Cardiology (JACC), egnite, Inc. today announced that it has expanded the company’s focus […]
Pulse Technologies’ Electrode Surface Treatment Chosen for Cardiac Device
Pulse Technologies’ HSR™ electrode surface treatment is now part of Cardionomic’s Cardiac Pulmonary Nerve Stimulation (CPNS) System for treating heart failure. QUAKERTOWN, Pa., May 16, 2022 /PRNewswire/ — Pulse Technologies Inc. has announced that its proprietary Hierarchical Surface Restructuring (HSR™) technology is being utilized as part of Cardionomic’s Cardiac Pulmonary Nerve Stimulation […]
Acutus Medical completes enrollment in IDE trial with its AcQBlate® FORCE Sensing Ablation System
CARLSBAD, Calif., May 13, 2022 (GLOBE NEWSWIRE) — Acutus Medical (Nasdaq: AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, today announced successful completion of patient enrollment in the company’s AcQForce™ Flutter Investigational Device Exemption (IDE) clinical trial which enrolled 110 patients at […]
Impulse Dynamics Announces First Implants of Optimizer Smart Mini
Company Is Committed to Innovation for Patients Living With Heart Failure MARLTON, N.J., May 10, 2022 (GLOBE NEWSWIRE) — Impulse Dynamics, a global medical device company dedicated to improving the lives of people with heart failure (HF), is announcing today the first implants of its newly launched Optimizer® Smart Mini, […]
OMRON Healthcare Unveils Long-term Corporate Vision, “Going for ZERO, Preventive Care for Health of Society”
– Aiming to Realize 3 Zeros: “Zero Cerebrovascular and Cardiovascular Events,” “Zero Aggravation of Respiratory Diseases” and “Zero Restrictions on Daily Activities Due to Chronic Pain” – KYOTO, Japan, May 10, 2022 /PRNewswire/ — In March 2022, OMRON Group announced a new long-term vision, “Shaping the Future 2030” (hereafter referred to as SF2030). In its commitment […]
Quantum Genomics Announces the End of Patient Recruitment for its Phase III Pivotal Study FRESH
PARIS, May 09, 2022 (GLOBE NEWSWIRE) — Quantum Genomics (Euronext Growth – FR0011648971 – ALQGC), a biopharmaceutical company specializing in the development of a new drug class directly targeting the brain to treat hypertension and heart failure, announces today that it has recruited all planned patients in its phase III pivotal study FRESH, […]



